Please login to the form below
hepatitis C
This page shows the latest hepatitis C news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
Sales of Gilead's hepatitis C virus (HCV) products and hepatitis delta virus (HDV) products increased by 18% to $220m, with a significant increase in sales of chronic hepatitis B virus
Latest news
-
Pfizer CEO says oral COVID-19 pill could be ready by the end of the year
Previously, protease inhibitors have been shown to be effective for the treatment of other viral pathogens, including HIV and hepatitis C virus when used alone or in combination with other antivirals.
-
FDA removes clinical hold on uniQure’s haemophilia gene therapy
This included a 25-year history of hepatitis C (HCV) as well as a history of hepatitis B (HBV).
-
Pfizer launches early study of COVID-19 antiviral therapeutic
Previously, protease inhibitors have been effective for the treatment of other viral pathogens, including HIV and hepatitis C virus, when administered alone and in combination with additional antivirals.
-
Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4
2020. Its hepatitis C virus (HCV) business also took a major hit, slipping by 33% to $423m in the fourth quarter and 30% to $2.1bn for the full year compared
-
Merck’s appeal to restore hepatitis C patent verdict against Gilead fails
Merck &Co’s appeal to restore a verdict against Gilead for infringing on a patent relating to a hepatitis C virus (HCV) treatment has been rejected by the US Supreme Court. ... Idenix discovered that a single type of modified ribonucleoside inhibits
Pfizer CEO says oral COVID-19 pill could be ready by the end of the year
FDA removes clinical hold on uniQure’s haemophilia gene therapy
Pfizer launches early study of COVID-19 antiviral therapeutic
Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4
Merck’s appeal to restore hepatitis C patent verdict against Gilead fails
More from news
Approximately 99 fully matching, plus 269 partially matching documents found.
Latest Intelligence
-
As the opioid crisis grabs the headlines, the search for safe treatments continues
The figure I use is 70-60-50. It reduces the mortality risk by 70%, lowers the risk of hepatitis C infection by 60% and has a 50% lower risk of
-
The Golden Goose
When the NHS finally did approve the life-saving hepatitis C treatments, it rationed access to only the sickest patients.
-
25 Women Leaders in UK Healthcare (part 2)
It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... After all this time, Hilary said she has to remind her team how remarkable the
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
The huge global success of Netflix has also made it a reference point, with health payers in the US and Australia recently signing ‘subscription’ arrangements to finance expanded spending on hepatitis
-
Vertex: a vision of treating all CF patients worldwide draws closer
a decade of trial and error, the company had a huge breakthrough drug on its hands: hepatitis C treatment Incivek.
As the opioid crisis grabs the headlines, the search for safe treatments continues
The Golden Goose
25 Women Leaders in UK Healthcare (part 2)
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Vertex: a vision of treating all CF patients worldwide draws closer
More from intelligence
Approximately 2 fully matching, plus 38 partially matching documents found.
Latest appointments
-
Red Door Unlimited appoints new digital strategy head
Prior to joining the agency, Morgan worked on accounts in patient advocacy for cancer immunotherapy, hepatitis C treatments and migraines for Firstlight PR and Hill and Knowlton Strategies.
-
Packer Forbes appoints Jade McCudden
McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.
-
Clark Health Communications make three team additions
range of therapy areas including hepatitis C, rare disease and gynaecology.
-
Cidara Therapeutics makes senior appointments
He joins from BMS, where he served as VP of the US viral hepatitis franchise, which is responsible for leading the US launch platform in hepatitis C and running the hepatitis
-
Medivir names new CEO
His other roles include CEO of Pfizer's business in Sweden. Commenting on his new position, he highlighted Medivir's work with Johnson &Johnson to develop the hepatitis C treatment Olysio
Red Door Unlimited appoints new digital strategy head
Packer Forbes appoints Jade McCudden
Clark Health Communications make three team additions
Cidara Therapeutics makes senior appointments
Medivir names new CEO
More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest from PMHub
-
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era
Insurance carve outs, reinsurance and specific contractual arrangements. The “Netflix” example of the Louisiana state approach to hepatitis C elimination which is based on unlimited access for a pre-specified budget
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
in rare diseases such as Gaucher disease and Cushing’s disease and in hepatitis C. She also has experience in cardiovascular disease, haematology and infectious diseases.
-
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
For the third year in a row, the IOTOD conference dedicated an entire session to hepatitis C virus (HCV).
-
TVF Communications shortlisted for the second year in a row for Writing Excellence award at Communique 2017
We created an eLearning Programme that was initiated to educate internal AbbVie stakeholders on hepatitis C virus (HCV).
-
Access and elimination: the future of DAAs in hepatitis C
the treatment paradigm and the long-term prognosis for hepatitis C. . ... The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for
More from PMHub
Approximately 2 fully matching, plus 11 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Planner
-
Salary TBC
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Account Manager
-
Salary TBC
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- Sanofi’s C1s inhibitor sutimlimab hits the mark in late-stage CAD study
- Israel finds a ‘probable link’ between Pfizer vaccine and myocarditis cases
- Your clinical trial participants are precious, so treat them as such
- Live Webinar: Helping Patients Become Active Participants in Their Own Care
- Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
- Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3
- The power of communication: Engaging diverse groups in healthcare
- US trial data shows Novavax’s COVID-19 vaccine is 90% effective
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- Diversity and inclusion in clinical trials
- Nicky Hutchens appointed as deputy managing director at Four Health
- FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
- Lucid Group acquires US-based strategic brand consultants DiD
- Novo Nordisk says Victoza outperforms SGLT2 inhibitors
PMHub
11 London
The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...
Latest intelligence
- Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
- Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....
- The power of communication: Engaging diverse groups in healthcare
- Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...
- Building the hospital of the future
- Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
